243 related articles for article (PubMed ID: 2522344)
1. Cyclophosphamide-induced immunologically mediated regression of a cyclophosphamide-resistant murine tumor: a consequence of eliminating precursor L3T4+ suppressor T-cells.
Awwad M; North RJ
Cancer Res; 1989 Apr; 49(7):1649-54. PubMed ID: 2522344
[TBL] [Abstract][Full Text] [Related]
2. Cyclophosphamide-induced tumour regression of cyclophosphamide-resistant L5178Y lymphoma through suppressor cells elimination.
Andrade-Mena CE
Int J Tissue React; 1994; 16(2):95-103. PubMed ID: 7960506
[TBL] [Abstract][Full Text] [Related]
3. Some characteristics of the cyclophosphamide-induced immunopotentiating cells in the spleen of mice bearing a large MOPC-315 tumor.
Mokyr MB; Ye QW
Cancer Res; 1985 Oct; 45(10):4932-9. PubMed ID: 4027979
[TBL] [Abstract][Full Text] [Related]
4. Cellular basis of immunologic interactions in adoptive T cell therapy of established metastases from a syngeneic murine sarcoma.
Ward BA; Shu S; Chou T; Perry-Lalley D; Chang AE
J Immunol; 1988 Aug; 141(3):1047-53. PubMed ID: 3260908
[TBL] [Abstract][Full Text] [Related]
5. Effect of low dose cyclophosphamide on the immune system of cancer patients: depletion of CD4+, 2H4+ suppressor-inducer T-cells.
Berd D; Mastrangelo MJ
Cancer Res; 1988 Mar; 48(6):1671-5. PubMed ID: 2830969
[TBL] [Abstract][Full Text] [Related]
6. Tumor-specific chemoimmunotherapy of murine fibrosarcoma using tumor-specific transplantation antigen, cyclophosphamide, and interleukin-2.
Naito K; Nomi S; Komichi H; Ueda Y; Yamagishi H; Oka T; Pellis NR; Kahan BD
Cancer Detect Prev; 1992; 16(5-6):321-7. PubMed ID: 1361881
[TBL] [Abstract][Full Text] [Related]
7. A role of L3T4+ antigen in the Con A response of regenerating splenic L3T4+ T cells after Cy treatment.
Ikezawa Z; Sato M; Aoki I
Immunology; 1987 Mar; 60(3):375-82. PubMed ID: 3106196
[TBL] [Abstract][Full Text] [Related]
8. In vitro differentiation of T-cells capable of mediating the regression of established syngeneic tumors in mice.
Shu S; Chou T; Rosenberg SA
Cancer Res; 1987 Mar; 47(5):1354-60. PubMed ID: 3102046
[TBL] [Abstract][Full Text] [Related]
9. Effect of continuous administration of interleukin 2 on active specific chemoimmunotherapy with extracted tumor-specific transplantation antigen and cyclophosphamide.
Naito K; Pellis NR; Kahan BD
Cancer Res; 1988 Jan; 48(1):101-8. PubMed ID: 3257158
[TBL] [Abstract][Full Text] [Related]
10. Cellular interactions and the role of interleukin 2 in the expression and induction of immunity against a syngeneic murine sarcoma.
Chou T; Shu S
J Immunol; 1987 Sep; 139(6):2103-9. PubMed ID: 2957448
[TBL] [Abstract][Full Text] [Related]
11. Further observations on the effect of cyclophosphamide on intratumor and peripheral leukocyte levels.
Evans R
Am J Pathol; 1980 Jun; 99(3):667-84. PubMed ID: 7386598
[TBL] [Abstract][Full Text] [Related]
12. Importance of signaling via the IFN-alpha/beta receptor on host cells for the realization of the therapeutic benefits of cyclophosphamide for mice bearing a large MOPC-315 tumor.
Mokyr MB; Place AT; Artwohl JE; Valli VE
Cancer Immunol Immunother; 2006 Apr; 55(4):459-68. PubMed ID: 15965646
[TBL] [Abstract][Full Text] [Related]
13. Role of antitumor immunity in cyclophosphamide-induced rejection of subcutaneous nonpalpable MOPC-315 tumors.
Mokyr MB; Hengst JC; Dray S
Cancer Res; 1982 Mar; 42(3):974-9. PubMed ID: 6977410
[TBL] [Abstract][Full Text] [Related]
14. Importance of Lyt-2+ T-cells in the resistance of melphalan-cured MOPC-315 tumor bearers to a challenge with MOPC-315 tumor cells.
Barker E; Mokyr MB
Cancer Res; 1988 Sep; 48(17):4834-42. PubMed ID: 3261626
[TBL] [Abstract][Full Text] [Related]
15. Antigen-antibody complexes generate Lyt 1 inducers of suppressor cells.
Rao VS; Bennett JA; Shen FW; Gershon RK; Mitchell MS
J Immunol; 1980 Jul; 125(1):63-7. PubMed ID: 6966663
[TBL] [Abstract][Full Text] [Related]
16. Induction by cyclophosphamide administration of two distinct anti-tumor effector cells at tumor site and spleen of mice transplanted with MOPC-104E plasmacytoma.
Nio Y; Ohgaki K; Tobe T
J Clin Lab Immunol; 1989 May; 29(1):37-43. PubMed ID: 2534133
[TBL] [Abstract][Full Text] [Related]
17. The role of suppressor T cells in BCNU-mediated rejection of a syngeneic tumor.
Nagarkatti M; Kaplan AM
J Immunol; 1985 Aug; 135(2):1510-7. PubMed ID: 3159794
[TBL] [Abstract][Full Text] [Related]
18. Intratumor gene expression after adoptive immunotherapy in a murine tumor model. Regulation of messenger RNA levels associated with the differential expansion of tumor-infiltrating lymphocytes.
Evans R; Kamdar SJ; Duffy T; Edison L
J Immunol; 1993 Jan; 150(1):177-84. PubMed ID: 8417123
[TBL] [Abstract][Full Text] [Related]
19. Suppression of secondary cellular immunity to a tumor allograft by cyclophosphamide and 1,3-bis(2-chloroethyl)-1-nitrosourea.
Einstein AB; Fass L; Fefer A
Cancer Res; 1975 Mar; 35(3):492-6. PubMed ID: 1078784
[TBL] [Abstract][Full Text] [Related]
20. Effect of cyclophosphamide on spleen cell suppressor activity and tumour growth in mice.
Larsen FS; Spärck JV
Acta Pathol Microbiol Immunol Scand C; 1983 Oct; 91(5):323-33. PubMed ID: 6229132
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]